Analysis of Pfizer's Latest 13F Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PFE?
Source: NASDAQ.COM
- Holding Overview: As of March 31, 2026, 25 hedge funds reported holding Pfizer (PFE) in their 13F filings, indicating ongoing market interest in the stock.
- Position Changes: Among these funds, 9 increased their positions while 10 decreased them between December 31, 2025, and March 31, 2026, reflecting a divergence in market sentiment.
- Aggregate Share Growth: Hedge funds collectively increased their holdings by 13,367,375 shares, raising the total from 262,596,852 to 275,964,227 shares, which represents an approximate 5.09% increase, suggesting optimism about Pfizer's future performance.
- Key Fund Movements: Notably, Team Financial Group LLC and Tradewinds LLC exited their positions in Pfizer common stock during this period, which may indicate a shift in their outlook on the stock, warranting investor attention regarding potential impacts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.450
Low
24.00
Averages
28.56
High
35.00
Current: 26.450
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Set to Report Earnings with Flat Revenue Expectations
- Earnings Preview: Pfizer is set to report earnings before the bell on Tuesday, with market expectations for flat revenue year-over-year, indicating a potential recovery from the 7.8% decline recorded in the same quarter last year.
- Revenue Performance: Last quarter, Pfizer reported revenues of $17.56 billion, down 1.2% year-over-year, which, while beating analyst expectations, showed a significant miss on organic revenue estimates, highlighting ongoing challenges for the company.
- Market Sentiment: Over the past month, Pfizer's stock has declined by 5.2%, contrasting sharply with peers like Eli Lilly and Merck, which reported revenue growth of 55.5% and 4.9%, respectively, indicating Pfizer's competitive disadvantages.
- Analyst Expectations: With an average analyst price target of $29.00 against a current share price of $26.38, there is a cautious outlook on Pfizer's future performance, especially as most analysts have revised their revenue estimates downward.
See More
Novavax Exceeds Expectations in Q1 Financials, Shares Rise
- Strong Financial Performance: Novavax's Q1 results exceeded expectations, with a $30M boost from a licensing deal with Pfizer, leading to total revenues of $97.3M, reflecting a 116% year-over-year growth.
- Decline in Vaccine Sales: Despite total revenues of $139.5M, down 79% year-over-year, the figure surpassed consensus estimates by $58.5M, primarily due to a significant drop in sales of the Nuvaxovid vaccine.
- Net Loss Reported: The company reported a net loss of $9.5M in Q1, a stark contrast to a net income of $518.6M in the same quarter last year, highlighting the impact of weak sales.
- Cost Reduction Initiatives: Novavax reiterated its full-year revenue guidance while increasing its expense reduction target for 2028 to over $500M, indicating progress in its ongoing cost-cutting efforts.
See More
Viking Therapeutics Accelerates Obesity Drug Development
- Clinical Trial Progress: Viking Therapeutics has fully enrolled both late-stage Vanquish studies ahead of schedule, with over 4,500 and 1,000 patients respectively, indicating the company's proactive positioning in the obesity drug market despite pressure from competitors like Pfizer.
- Financial Challenges: The company reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the previous year, while R&D expenses surged to $150.2 million, reflecting high investment in obesity drug development.
- Intensifying Market Competition: Pfizer highlighted obesity drugs as a major future growth driver in its latest earnings report, anticipating that its $10 billion Metsera deal will lead to strong growth post-2028, thereby intensifying competition in the obesity drug market.
- Investor Sentiment: Despite financial pressures, VKTX maintains an 'extremely bullish' sentiment among retail investors, with a 700% surge in message volume over 24 hours, indicating strong market confidence in its obesity drug VK2735.
See More
China Emerges as a Leader in Global Pharmaceutical Innovation
- Earnings Beat: Waters reported adjusted earnings per share of $2.70, exceeding estimates of $2.31, with revenue of $1.27 billion surpassing the $1.20 billion forecast, indicating strong performance driven by the pharmaceutical segment, particularly in China.
- China's Market Growth: The pharmaceutical segment grew 14%, with China leading at over 50% growth, while India and Japan saw low-teens growth, highlighting China's rapid emergence as a key player in global pharmaceutical innovation and market expansion.
- Innovation-Driven Transformation: Despite a decline in China's generic drug market due to price restrictions, the development of innovative drugs is reshaping the landscape, with contract manufacturers rapidly scaling up to manage the entire process from discovery to development, aiming to create entities akin to Pfizer or AstraZeneca.
- Regional Performance: Asia's growth was nearly 30%, while the Americas and Europe achieved high single-digit growth, reflecting a diversified development trend in the global pharmaceutical market, with Waters' success underscoring the effectiveness of this strategic approach.
See More
Investment Opportunities in Dividend Stocks
- Resilience of Realty Income: Realty Income's stock has fallen 20% from its March peak, yet its occupancy rate above 98% and stable 5.1% dividend yield demonstrate its ability to withstand economic turbulence, providing investors with an opportunity to enter at an elevated yield.
- Potential of Brookfield Renewable: A 20% pullback in Brookfield Renewable's stock has pushed its dividend yield up to 4.4%, and despite geopolitical and interest rate pressures, the company is still on track for annual dividend growth of 5% to 9%, reflecting the long-term growth potential of renewable energy.
- Transformation Opportunity for Pfizer: Although Pfizer's stock is down 55% from its 2021 peak, the company is actively developing new drugs, expecting to generate $15 billion to $20 billion in new revenue by 2030, while offering a stable 6.54% dividend yield for investors.
- Market Sentiment and Timing: The current pessimism surrounding dividend stocks may lead investors to underestimate the fundamentals of companies like Realty Income and Brookfield Renewable, suggesting that now is an opportune time to invest in these resilient firms.
See More
Pfizer Reports Strong Q1 2026 Earnings with Positive Outlook
- Performance Exceeds Expectations: Pfizer reported Q1 2026 revenues of $14.5 billion and adjusted EPS of $0.75, both surpassing analyst estimates, indicating strong performance from new products and acquired assets, which is expected to drive future growth.
- Favorable Legal Developments: Recent settlements regarding Vyndamax patent infringements and the Belgian Comirnaty contracts are anticipated to significantly enhance cash flow and revenue growth prospects post-2029, with management expressing confidence in a high single-digit CAGR over the next five years.
- Strong Product Growth: Launched and acquired products achieved 22% operational growth in Q1, with Nurtec contributing 41% operational growth, demonstrating the company's competitive strength and robust product demand, further solidifying its market position.
- Ongoing Cost Control: Pfizer's adjusted operating margin stood at 38%, with expectations to achieve $7.2 billion in net cost savings by the end of 2026, showcasing effective cost management and resource allocation that supports dividend maintenance and future capital returns.
See More
Pfizer Set to Report Earnings with Flat Revenue Expectations
- Earnings Preview: Pfizer is set to report earnings before the bell on Tuesday, with market expectations for flat revenue year-over-year, indicating a potential recovery from the 7.8% decline recorded in the same quarter last year.
- Revenue Performance: Last quarter, Pfizer reported revenues of $17.56 billion, down 1.2% year-over-year, which, while beating analyst expectations, showed a significant miss on organic revenue estimates, highlighting ongoing challenges for the company.
- Market Sentiment: Over the past month, Pfizer's stock has declined by 5.2%, contrasting sharply with peers like Eli Lilly and Merck, which reported revenue growth of 55.5% and 4.9%, respectively, indicating Pfizer's competitive disadvantages.
- Analyst Expectations: With an average analyst price target of $29.00 against a current share price of $26.38, there is a cautious outlook on Pfizer's future performance, especially as most analysts have revised their revenue estimates downward.
See More
Novavax Exceeds Expectations in Q1 Financials, Shares Rise
- Strong Financial Performance: Novavax's Q1 results exceeded expectations, with a $30M boost from a licensing deal with Pfizer, leading to total revenues of $97.3M, reflecting a 116% year-over-year growth.
- Decline in Vaccine Sales: Despite total revenues of $139.5M, down 79% year-over-year, the figure surpassed consensus estimates by $58.5M, primarily due to a significant drop in sales of the Nuvaxovid vaccine.
- Net Loss Reported: The company reported a net loss of $9.5M in Q1, a stark contrast to a net income of $518.6M in the same quarter last year, highlighting the impact of weak sales.
- Cost Reduction Initiatives: Novavax reiterated its full-year revenue guidance while increasing its expense reduction target for 2028 to over $500M, indicating progress in its ongoing cost-cutting efforts.
See More
Viking Therapeutics Accelerates Obesity Drug Development
- Clinical Trial Progress: Viking Therapeutics has fully enrolled both late-stage Vanquish studies ahead of schedule, with over 4,500 and 1,000 patients respectively, indicating the company's proactive positioning in the obesity drug market despite pressure from competitors like Pfizer.
- Financial Challenges: The company reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the previous year, while R&D expenses surged to $150.2 million, reflecting high investment in obesity drug development.
- Intensifying Market Competition: Pfizer highlighted obesity drugs as a major future growth driver in its latest earnings report, anticipating that its $10 billion Metsera deal will lead to strong growth post-2028, thereby intensifying competition in the obesity drug market.
- Investor Sentiment: Despite financial pressures, VKTX maintains an 'extremely bullish' sentiment among retail investors, with a 700% surge in message volume over 24 hours, indicating strong market confidence in its obesity drug VK2735.
See More
China Emerges as a Leader in Global Pharmaceutical Innovation
- Earnings Beat: Waters reported adjusted earnings per share of $2.70, exceeding estimates of $2.31, with revenue of $1.27 billion surpassing the $1.20 billion forecast, indicating strong performance driven by the pharmaceutical segment, particularly in China.
- China's Market Growth: The pharmaceutical segment grew 14%, with China leading at over 50% growth, while India and Japan saw low-teens growth, highlighting China's rapid emergence as a key player in global pharmaceutical innovation and market expansion.
- Innovation-Driven Transformation: Despite a decline in China's generic drug market due to price restrictions, the development of innovative drugs is reshaping the landscape, with contract manufacturers rapidly scaling up to manage the entire process from discovery to development, aiming to create entities akin to Pfizer or AstraZeneca.
- Regional Performance: Asia's growth was nearly 30%, while the Americas and Europe achieved high single-digit growth, reflecting a diversified development trend in the global pharmaceutical market, with Waters' success underscoring the effectiveness of this strategic approach.
See More
Investment Opportunities in Dividend Stocks
- Resilience of Realty Income: Realty Income's stock has fallen 20% from its March peak, yet its occupancy rate above 98% and stable 5.1% dividend yield demonstrate its ability to withstand economic turbulence, providing investors with an opportunity to enter at an elevated yield.
- Potential of Brookfield Renewable: A 20% pullback in Brookfield Renewable's stock has pushed its dividend yield up to 4.4%, and despite geopolitical and interest rate pressures, the company is still on track for annual dividend growth of 5% to 9%, reflecting the long-term growth potential of renewable energy.
- Transformation Opportunity for Pfizer: Although Pfizer's stock is down 55% from its 2021 peak, the company is actively developing new drugs, expecting to generate $15 billion to $20 billion in new revenue by 2030, while offering a stable 6.54% dividend yield for investors.
- Market Sentiment and Timing: The current pessimism surrounding dividend stocks may lead investors to underestimate the fundamentals of companies like Realty Income and Brookfield Renewable, suggesting that now is an opportune time to invest in these resilient firms.
See More
Pfizer Reports Strong Q1 2026 Earnings with Positive Outlook
- Performance Exceeds Expectations: Pfizer reported Q1 2026 revenues of $14.5 billion and adjusted EPS of $0.75, both surpassing analyst estimates, indicating strong performance from new products and acquired assets, which is expected to drive future growth.
- Favorable Legal Developments: Recent settlements regarding Vyndamax patent infringements and the Belgian Comirnaty contracts are anticipated to significantly enhance cash flow and revenue growth prospects post-2029, with management expressing confidence in a high single-digit CAGR over the next five years.
- Strong Product Growth: Launched and acquired products achieved 22% operational growth in Q1, with Nurtec contributing 41% operational growth, demonstrating the company's competitive strength and robust product demand, further solidifying its market position.
- Ongoing Cost Control: Pfizer's adjusted operating margin stood at 38%, with expectations to achieve $7.2 billion in net cost savings by the end of 2026, showcasing effective cost management and resource allocation that supports dividend maintenance and future capital returns.
See More
